Provectus Pharmaceuticals Inc. On 2005 Third Quarter Results
KNOXVILLE, Tenn., Nov. 15 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. , an innovative pharmaceutical company engaged in the research and development of breakthrough technologies for psoriasis, breast cancer and other serious diseases, announced today that significant operational and financial progress was made in the third quarter ended September 30, 2005. Financial results for the period can be found in the Form 10Q filed with the U.S. Securities and Exchange commission on November 14, 2005, which is accessible at the SEC website at http://www.sec.gov.
Significant milestones reached during and subsequent to the 2005 third quarter include:
- In August, the Company announced that the first group of subjects had completed treatment in its Phase 1 clinical trial of PV-10, also known as Provecta(TM), and that the treatment was well tolerated at the initial dose level. The study is being conducted at two dosage levels with both dosage levels having the potential for showing safety, preliminary efficacy, and the "bystander effect" in untreated lesions. - In early October, the Company began its second Phase 1 clinical trial of PV-10, the Company's lead cancer treatment, to treat malignant breast tumors. The study is designed to evaluate the safety and preliminary efficacy of PV-10 in five subjects with recurrent breast carcinoma. Following the treatment, subjects will then undergo standard surgery to remove their tumors, allowing study personnel to carefully assess the effects of PV-10 in breast cancer tissue and surrounding normal tissue. - Also in October, the Company announced that its President, Timothy Scott, Ph.D., received the prestigious "Distinguished Achievement Award" from the College of Engineering of the University of Wisconsin, Madison. The award is presented to distinguished educators and alumni who have made significant contributions to science, industry, the school of engineering and the community. Dr. Scott received his doctorate in Chemical Engineering from the university. - During the third quarter, the Company launched an active investor outreach program in which it is presenting at a series of luncheon events and financial conferences to individuals and groups in the investment communities in cities across the US, including New York, Los Angeles, Washington, DC, and Philadelphia.
Provectus CEO Craig Dees, Ph.D., said, "Clinical progress continued to accelerate in the third quarter as we prepared to begin new trials evaluating the use of PV-10 to treat breast cancer and as positive preliminary results began to emerge from ongoing trials for melanoma. We remain very enthusiastic about the ability of our injectable agents to battle cancerous tumors without the need for systemic chemotherapy or radiation, and we eagerly await additional supporting clinical data to be released in the coming months."
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals, Inc. is an innovative pharmaceutical company actively engaged in the design, development, and marketing of pharmaceutical technologies for the treatment of breast cancer, liver cancer, and metastatic melanoma. In addition, Provectus is preparing to begin Phase 2 clinical studies for the Company's topical agent Xantryl(TM), a treatment for psoriasis.
The Company's offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865 769 4011. For more information, contact the Company at firstname.lastname@example.org or visit the corporate Web site: http://www.pvct.com.
This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward- looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward- looking statements.Provectus Pharmaceuticals, Inc.
CONTACT: Matt Clawson, Investors, Allen & Caron Inc., +1-949-474-4300,email@example.com; or Peter Culpepper, Provectus Pharmaceuticals Inc.,+1-865-769-4011, firstname.lastname@example.org
Web site: http://www.pvct.com/